Potassium channel tetramerization domain-containing protein 13 (KCTD13)

KCTD13 encodes a non-channel, soluble adapter protein containing a BTB/POZ domain, functioning as a substrate-specific modulator in Cullin3-RING E3 ubiquitin ligase complexes[2][3][5]. It negatively regulates RhoA-mediated signaling, impacting neural progenitor proliferation, synaptic transmission, and neuronal migration during cortical development[1][5]. Dosage imbalance of KCTD13 leads to mirrored neuroanatomical phenotypes such as microcephaly or macrocephaly, as observed in model organisms and human patients[1]. Loss-of-function or overexpression is associated with cognitive deficits and neuropsychiatric disorders, notably in the context of 16p11.2 chromosome copy number variations[1][5]. KCTD13 participates in protein-protein interactions (e.g., with PCNA)[4], but is not a potassium channel, ion transporter, or receptor[2][3]. Its adapter function in ubiquitin-mediated protein degradation makes it a molecular target for research in neurodevelopmental and synaptic disorders.\n\nIf additional specificity about drug interactions or mechanisms arises in future research, these fields can be updated, but current evidence does not support direct drug targeting of KCTD13.

Other names

BACURD1PDIP1POLDIP1hBACURD1FKSG86Polymerase delta-interacting protein 1TNFAIP1-like protein

For hypothetical drugs: modulation of E3 ligase adapter function, alteration of protein ubiquitination/degradation, RhoA pathway inhibition